Inactive Instrument

Oncomed Pharmaceuticals Inc Stock price

Equities

US68234X1028

Biotechnology & Medical Research

Dynamic Chart
Celgene Corporation Announces Update on Etigilimab Partnership CI
OncoMed Pharmaceuticals, Inc. Announces Executive Resignations in Connection with the Merger Agreement CI
OncoMed Pharmaceuticals, Inc.(NasdaqGM:OMED) dropped from NASDAQ Composite Index CI
Mereo BioPharma Group plc completed the acquisition of OncoMed Pharmaceuticals, Inc. from Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC and Biotechnology Value Trading Fund OS LP managed by BVF Partners LP and others. CI
OncoMed Pharmaceuticals, Inc.(NasdaqGS:OMED) dropped from S&P TMI Index CI
OncoMed Pharmaceuticals, Inc. Declares Special Dividend of Contingent Value Rights, Payable on April 5, 2019 CI
OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2018 CI
Oncomed Pharmaceuticals, Inc. Announces Executive Changes CI
Transcript : Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc. - M&A Call
Mereo BioPharma Group plc agreed to acquire OncoMed Pharmaceuticals, Inc. for $57.4 million. CI
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018 CI
Celgene Notifies OncoMed Pharmaceuticals, Inc. of Its Decision Not to Exercise Option to License Rosmantuzumab and Subsequently Terminated the Companies’ Collaboration Agreement with Respect to Rosmantuzumab, Effective February 12, 2019 CI
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting CI
OncoMed Pharmaceuticals, Inc. Announces Resignation of Denise Scots-Knight as Member of the Board CI
More news
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
More about the company
  1. Stock
  2. Equities
  3. Stock Oncomed Pharmaceuticals Inc - Nasdaq